阿尔茨海默病中的小质细胞:病变发生,机制和治疗潜力
Jifei Miao1,2, Haixia Ma3, Yang Yang3
1Shenzhen Bao'an Traditional Chinese Medicine Hospital, Shenzhen, China.
Frontiers in aging neuroscience
|July 3, 2023
概括
微质细胞通过影响神经炎症和神经元调节,在阿尔茨海默病 (AD) 发病过程中发挥关键作用. 了解这些细胞为AD药物发现提供了新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是脑蛋白聚集.
- 微质细胞,大脑的免疫细胞,越来越多地被认为在AD病变发生过程中发挥着关键作用.
- 功能障碍的微质细胞有助于AD中的神经炎症和神经元损伤.
研究的目的:
- 综合审查微质在阿尔茨海默病中的多方面的作用.
- 探索遗传因素,表型变化和AD中的微质的功能能力.
- 总结一下AD治疗的微质向药物发现的最新进展.
主要方法:
- 对阿尔茨海默氏症中微质细胞的当前研究的文献综述.
- 对微质参与的遗传,细胞和功能方面的分析.
- 对针对微质通路的新兴治疗策略的调查.
主要成果:
- 微质遗传决定因素显著影响AD风险和进展.
- 微细胞的表型 (例如,亲炎性与食性) 影响疾病的发展轨迹.
- 微质功能障碍影响AD模型中的突触可塑性和神经元健康.
- 向微质通路显示出新型AD治疗的前景.
结论:
- 微质是阿尔茨海默氏症病理学的核心参与者.
- 调节微质功能是阿尔茨海默病的一个有希望的治疗策略.
- 对微质生物学进行进一步的研究对于有效的AD治疗开发至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
01:22Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220